Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc, dated April 14, 2025, reports a transaction in own shares. Haleon is a global leader in consumer health with a portfolio spanning Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS). The filing details a specific share repurchase executed under a buyback programme announced on March 28, 2025.
Key Financial Metrics and Transaction Details
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on the following share buyback transaction executed on April 11, 2025:
- Shares Purchased: 887,346 ordinary shares
- Highest Price Paid: 375.70 pence per share
- Lowest Price Paid: 368.70 pence per share
- Volume Weighted Average Price: 373.44 pence per share
- Post-Transaction Share Capital: 9,030,422,518 ordinary shares of £0.01 each
- Treasury Shares Held: 4,080,205
- Voting Shares Outstanding: 9,026,342,518
Material Changes
The primary material change reported is the reduction of the Company's share capital through the cancellation of 887,346 shares. Consequently, the number of ordinary shares with voting rights has been updated to 9,026,342,518. No other material changes to financial performance or operations are disclosed in this specific filing.
Guidance, Outlook, and Risks
This filing contains no forward-looking guidance, management commentary on future outlook, or discussion of risks and contingencies. It is a regulatory disclosure of a completed transaction in accordance with the Market Abuse Regulation (EU) No 596/2014 as applied in the UK. The filing explicitly states it does not constitute an offer or solicitation of an offer for securities.
Key Facts for Investor Verification
- Verify the total number of voting shares (9,026,342,518) for compliance with FCA Disclosure Guidance and Transparency Rules.
- Confirm the execution price range (368.70p to 375.70p) against market data for April 11, 2025.
- Review the full trade breakdown available via the provided London Stock Exchange link for granular transaction details.
- Note that this filing does not contain financial performance data; refer to the most recent Form 20-F or quarterly reports for revenue and earnings.